Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies.

Lachno DR, Romeo MJ, Siemers ER, Vanderstichele H, Coart E, Konrad RJ, Zajac JJ, Talbot JA, Jensen HF, Sethuraman G, Demattos RB, May PC, Dean RA.

J Alzheimers Dis. 2011;26(3):531-41. doi: 10.3233/JAD-2011-110296.

PMID:
21694458
2.

Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab.

Lachno DR, Evert BA, Vanderstichele H, Robertson M, Demattos RB, Konrad RJ, Talbot JA, Racke MM, Dean RA.

J Alzheimers Dis. 2013;34(4):897-910. doi: 10.3233/JAD-122317.

PMID:
23302661
3.

Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.

Carlson C, Estergard W, Oh J, Suhy J, Jack CR Jr, Siemers E, Barakos J.

Alzheimers Dement. 2011 Jul;7(4):396-401. doi: 10.1016/j.jalz.2011.05.2353.

PMID:
21784350
4.

Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.

Ibach B, Binder H, Dragon M, Poljansky S, Haen E, Schmitz E, Koch H, Putzhammer A, Kluenemann H, Wieland W, Hajak G.

Neurobiol Aging. 2006 Sep;27(9):1202-11. Epub 2005 Aug 8.

PMID:
16085339
5.

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, Rosengren L, Vanmechelen E, Blennow K.

Clin Chem. 2005 Feb;51(2):336-45. Epub 2004 Nov 24.

6.

Longitudinal stability of CSF biomarkers in Alzheimer's disease.

Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P, Basun H, Andreasen N.

Neurosci Lett. 2007 May 23;419(1):18-22. Epub 2007 Apr 6.

PMID:
17482358
7.

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.

Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K.

Arch Gen Psychiatry. 2004 Jan;61(1):95-102.

PMID:
14706948
8.

No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.

Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De Leenheir E, Martin JJ, Vanmechelen E, Van Broeckhoven C, De Deyn PP.

Brain. 2007 Sep;130(Pt 9):2320-6. Epub 2007 Jun 22.

9.

Validation and Clinical Utility of ELISA Methods for Quantification of Amyloid-β of Peptides in Cerebrospinal Fluid Specimens from Alzheimer’s Disease Studies.

Lachno DR, Evert BA, Maloney K, Willis BA, Talbot JA, Vandijck M, Dean RA.

J Alzheimers Dis. 2015;45(2):527-42.

PMID:
25547638
10.

Validation of a multiplex assay for simultaneous quantification of amyloid-β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics.

Lachno DR, Emerson JK, Vanderstichele H, Gonzales C, Martényi F, Konrad RJ, Talbot JA, Lowe SL, Oefinger PE, Dean RA.

J Alzheimers Dis. 2012;32(4):905-18. doi: 10.3233/JAD-2012-121075.

PMID:
22886018
11.

Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia.

de Jong D, Jansen RW, Kremer BP, Verbeek MM.

J Gerontol A Biol Sci Med Sci. 2006 Jul;61(7):755-8.

PMID:
16870640
12.

Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia.

Laske C, Stransky E, Fritsche A, Eschweiler GW, Leyhe T.

Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):80-5. doi: 10.1007/s00406-008-0838-3. Epub 2008 Sep 19.

PMID:
18806919
13.

Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia.

Boban M, Grbić K, Mladinov M, Hof PR, Süssmair C, Ackl N, Stanić G, Bader B, Danek A, Simić G.

Coll Antropol. 2008 Jan;32 Suppl 1:31-6.

PMID:
18405055
14.

Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations.

Fortea J, Lladó A, Bosch B, Antonell A, Oliva R, Molinuevo JL, Sánchez-Valle R.

Neurodegener Dis. 2011;8(4):202-7. doi: 10.1159/000322229. Epub 2011 Jan 5.

PMID:
21212633
15.

BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.

Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, Hack CE, Veerhuis R.

J Alzheimers Dis. 2010;20(1):253-60. doi: 10.3233/JAD-2010-1367.

PMID:
20164582
16.

Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan.

Nishimura T, Takeda M, Nakamura Y, Yosbida Y, Arai H, Sasaki H, Shouji M, Hirai S, Khise K, Tanaka K, Hamamoto M, Yamamoto H, Matsubayashi T, Urakami K, Adachi Y, Nakashima K, Toji H, Nakamura S, Yoshida H.

Methods Find Exp Clin Pharmacol. 1998 Apr;20(3):227-35.

PMID:
9646285
17.

Abeta1-42 Detection in CSF of Alzheimer's disease is influenced by temperature: indication of reversible Abeta1-42 aggregation?

Sancesario GM, Esposito Z, Nuccetelli M, Bernardini S, Sorge R, Martorana A, Federici G, Bernardi G, Sancesario G.

Exp Neurol. 2010 Jun;223(2):371-6. doi: 10.1016/j.expneurol.2009.07.028. Epub 2009 Aug 5.

PMID:
19664624
18.

Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia.

Jia JP, Meng R, Sun YX, Sun WJ, Ji XM, Jia LF.

Neurosci Lett. 2005 Jul 22-29;383(1-2):12-6. Epub 2005 Apr 25.

PMID:
15936505
19.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
20.

[The measurement of phosphorylated tau in human cerebrospinal fluid as a diagnostic marker for Alzheimer's disease].

Urakami K, Ito N, Arai H, Ishiguro K, Ohno H, Nakashima K.

Seishin Shinkeigaku Zasshi. 2003;105(4):393-7. Japanese.

PMID:
12806900
Items per page

Supplemental Content

Write to the Help Desk